QUALITY BY DESIGN AND CHARACTERIZATION OF EDARAVONE SLN TO IMPROVE BRAIN DELIVERY BY NASAL ROUTE FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Objective: The present study aims at formulation development of solid lipid nanoparticles of Edaravone (EDN), for nasal administration to improve the permeation through blood blood-brain barrier for therapeutically effect on Alzheimer’s disease. Methods: Solid lipid nanoparticles (SLN) are formulated by using the lipid core of Glyceryl monostearate and Tween80 as surfactant through emulsification, solvent evaporation technique and optimized by using 32 central composite design (CCD) secondary overlay plots. Selection of the optimized formulation based on the dependable factors like entrapment efficiency (EE), particle size, polydispersity index (PDI), zeta potential and drug release studies. The selected optimized formulation was subjected to test the behavioral changes in Wister rats. Results: The final optimized formulation was observed as particle size of